Alexander Angelov

Senior Director, Data & Analytics @CluePoints

London, GB

We offer Sponsors and CROs a better way of identifying, visualizing, managing, and documenting trial risks that could compromise patient safety and delay the approval of Investigational Products. Underpinned by Central Statistical Monitoring, a technique that’s currently being investigated by the Food and Drug Administration (FDA) for selecting sites for inspection, our cloud-based products are deployed to support traditional onsite monitoring, medical review and quality to drive a Risk-Based Approach to Study Execution (RBx) and ultimately, to achieve ICH E6 (R2) compliance.CluePoints’ solutions, all of which are cloud-based, are driven by Central Statistical Monitoring, a unique set of algorithms that interrogate clinical and operational data in real-time centrally to conveniently illuminate outliers and anomalies in data. The adoption of statistics to assist with quality oversight in trials is well documented. So much so, that the FDA extended its CRADA with CluePoints to further explore a data-driven approach to oversight in trials.

University of Oxford

Artificial Intelligence

University of South Wales

Master of Science, MSc Sustainable Business Risk Management

Harvard Business School

Leadership and Management

University of Southampton

Fundamentals of Data Science

Sofia University St. Kliment Ohridski

Bachelor of Science, BSc Statistics